CA
NZ
UK
AU
IND
US
The gap between the pre-market price and the offer is about 2.99 percent of theOffer Price(calculated). Closing is expected in early 2027, subject toShareholderapproval and expiry or termination of the Hart-Scott-Rodino waiting period. A go-shop period runs until December 11, 2026. Risks include a …
TheBusinesscombination closed on September 23, 2026. The company described about 5 GW of Louisiana projects in active development, including Amberjack, an advanced nuclear project of up to 1 GW. It is at the development stage, with noRevenuefrom operating plants. As aPenny Stockit can be …
Security subscriptions revenue rose 11 percent to USD 338.6 million, while non-GAAP diluted EPS was USD 2.49 versus USD 3.94 a year earlier. The company said it expects gradual improvement beginning in the fourth quarter and gave no numeric guidance. The company repurchased about …
The stock is down about 54.6 percent over the past month. The filing contained noRevenueorEarningsfigures, so the commercial impact cannot yet be measured, and thisPenny Stockcan swing widely.
Closing is expected in early 2027, subject toShareholderapproval and Hart-Scott-Rodino expiry or termination. A go-shop period runs until December 11, 2026, and the company said there is no assurance it will produce a superior offer. Completion risk remains.
Nasdaq issued a delisting determination on July 15, 2026. Stockholders'Equityof USD 2,091,324 was below the USD 2.5 million minimum, and the company later asked a Nasdaq Hearings Panel to confirm compliance, citing preliminary pro forma equity of USD 8,220,419 as of August 31, 2026. …
The 1-for-20 reverse split took effect on October 23, 2026, cutting Class A shares outstanding from 10,379,942 to approximately 518,997. The company said the split is intended to support compliance with Nasdaq's minimum bid price requirement and that there is no assurance it will …
Nasdaq issued a Staff Delisting Determination on October 13, 2026, and the company appealed the next day, which stays any delisting while a Hearings Panel reviews the matter. Shareholders approved a share consolidation on October 30, 2026. Half-yearRevenuerose 34 percent to USD 24.0 million. …
The latest release was the October 20, 2026 closing of a USD 3.75 million registered direct offering. First half 2026Revenuewas USD 12.94 million, up 26.01 percent, and the company completed 1-for-16 and 1-for-200 share combinations this year. The shares trade far below the USD …
In the efficacy population, 7 of 26 patients, or 27 percent, had no surgical papilloma removal over 12 months. The company expects a full commercial launch in the first quarter of 2027, and the FDA requires a draft confirmatory study protocol by the end …
Please wait processing your request...